PubRank

Maria Cristina Marzola

Author PubWeight™ 42.48‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging 2010 1.85
2 Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur J Nucl Med Mol Imaging 2011 1.53
3 Role of FDG-PET and PET/CT in the diagnosis and management of vasculitis. Eur J Radiol 2010 1.20
4 PET/CT imaging in different types of lung cancer: an overview. Eur J Radiol 2011 1.04
5 Choline PET/CT for prostate cancer: main clinical applications. Eur J Radiol 2010 1.02
6 Confirmatory tests in the diagnosis of brain death: comparison between SPECT and contrast angiography. Crit Care Med 2005 1.01
7 Increased serum thyroglobulin levels and negative imaging in thyroid cancer patients: are there sources of benign secretion? A speculative short review. Nucl Med Commun 2010 0.99
8 Role of ¹⁸F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer. Eur J Nucl Med Mol Imaging 2013 0.98
9 Molecular imaging of pulmonary nodules. AJR Am J Roentgenol 2014 0.93
10 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: a multicentre study. Eur J Radiol 2010 0.92
11 Fifteen different 18F-FDG PET/CT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy. Eur J Nucl Med Mol Imaging 2013 0.91
12 Anti-hypertensive treatment in pheochromocytoma and paraganglioma: current management and therapeutic features. Endocrine 2013 0.91
13 Recombinant human TSH and ablation of post-surgical thyroid remnants in differentiated thyroid cancer: the effect of pre-treatment with furosemide and furosemide plus lithium. Eur J Nucl Med Mol Imaging 2009 0.89
14 Value of (18)F-FDG PET for Predicting Response to Neoadjuvant Therapy in Rectal Cancer: Systematic Review and Meta-Analysis. AJR Am J Roentgenol 2015 0.88
15 Present and future of PET and PET/CT in gynaecologic malignancies. Eur J Radiol 2010 0.88
16 Noninvasive and invasive staging of ovarian cancer: review of the literature. Clin Nucl Med 2011 0.87
17 Intradermal lymphoscintigraphy at rest and after exercise: a new technique for the functional assessment of the lymphatic system in patients with lymphoedema. Nucl Med Commun 2010 0.87
18 Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. Eur J Radiol 2012 0.87
19 Imaging identifies submandibular ectopic thyroid tissue. Clin Nucl Med 2011 0.86
20 A new methodological approach for PET implementation in radiotherapy treatment planning. Nucl Med Commun 2012 0.85
21 Synthesis and quality control of 68Ga citrate for routine clinical PET. Nucl Med Commun 2009 0.85
22 Additional value of FDG-PET/CT in management of "solitary" liver metastases: preliminary results of a prospective multicenter study. Mol Imaging Biol 2009 0.83
23 Prostate-specific antigen kinetics and choline PET/CT in patients with biochemical relapse after primary treatment for prostate cancer. Nucl Med Commun 2011 0.83
24 F-18 FDG PET/CT in rectal carcinoma: where are we now? Clin Nucl Med 2011 0.82
25 Comparison between anatomical cross-sectional imaging and 18F-FDG PET/CT in the staging, restaging, treatment response, and long-term surveillance of squamous cell head and neck cancer: a systematic literature overview. Nucl Med Commun 2014 0.82
26 High risk of malignancy in patients with incidentally discovered adrenal masses: accuracy of adrenal imaging and image-guided fine-needle aspiration cytology. Tumori 2007 0.81
27 Proposal of a new 18F-FDG PET/CT predictor of response in rectal cancer treated by neoadjuvant chemoradiation therapy and comparison with PERCIST criteria. Clin Nucl Med 2013 0.81
28 Colorectal cancer: prognostic role of 18F-FDG-PET/CT. Abdom Imaging 2012 0.81
29 The role of fine-needle aspiration performed with liquid-based cytology in the surgical management of thyroid lesions. In Vivo 2010 0.81
30 Role and cost-effectiveness of adrenal imaging and image-guided FNA cytology in the management of incidentally discovered adrenal tumours. Anticancer Res 2005 0.80
31 Evaluation of incidentally discovered adrenal masses with PET and PET/CT. Eur J Radiol 2011 0.80
32 Intraoperative hand-held imaging γ-camera for sentinel node detection in patients with breast cancer: feasibility evaluation and preliminary experience on 16 patients. Clin Nucl Med 2013 0.79
33 18F-DOPA PET/CT biodistribution consideration in 107 consecutive patients with neuroendocrine tumours. Nucl Med Commun 2012 0.79
34 Evolving paradigms for successful molecular imaging of medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2012 0.79
35 ¹⁸F-FDG-PET/CT in malignant mesothelioma. Biomed Pharmacother 2013 0.78
36 Management of epithelial ovarian cancer from diagnosis to restaging: an overview of the role of imaging techniques with particular regard to the contribution of 18F-FDG PET/CT. Nucl Med Commun 2014 0.78
37 Usefulness of 99mTc-pertechnetate scintigraphy and fine-needle aspiration cytology in patients with solitary thyroid nodules and thyroid cancer. Anticancer Res 2004 0.77
38 Optimising (18)F-Choline PET/CT Acquisition Protocol in Prostate Cancer Patients. N Am J Med Sci 2012 0.77
39 FDG PET/CT in ovarian cancer: what about treatment response and prognosis? Clin Nucl Med 2012 0.77
40 Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy? Eur J Nucl Med Mol Imaging 2014 0.77
41 Non-Alzheimer types of neurodegenerative dementia: clinical and 18F-FDG-PET/CT pictures. Nucl Med Commun 2014 0.77
42 Usefulness of combined sestamibi scintimammography, axillary ultrasonography and FNA cytology in reducing the number of sentinel node procedures in patients with early-stage breast cancer. Anticancer Res 2009 0.77
43 Immunohistochemical evaluation of inflammatory and proliferative markers in adjacent normal thyroid tissue in patients undergoing total thyroidectomy: results of a preliminary study. J Exp Clin Cancer Res 2010 0.76
44 (68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2010 0.76
45 How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non-18F-FDG PET radiopharmaceuticals. Nucl Med Commun 2012 0.76
46 Proposal of a new acquisition protocol for bladder cancer visualization with 18F-FDG PET/CT. Clin Nucl Med 2015 0.76
47 Optimized protocol for (18)F-choline PET/CT in patients with biochemically relapsed prostate cancer: experiences on 250 consecutive cases. Clin Nucl Med 2015 0.76
48 Positron emission tomography for the evaluation of soft-tissue sarcomas and bone sarcomas. Eur J Nucl Med Mol Imaging 2009 0.75
49 ¹⁸F-FDG and new positron emitter radiotracers for detecting recurrent medullary thyroid carcinoma. J Med Imaging Radiat Oncol 2012 0.75
50 Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging. Nucl Med Commun 2013 0.75
51 Editorial comment to "Update on positron emission tomography for imaging of prostate cancer". Int J Urol 2013 0.75
52 Mini-invasive videoassisted thyroid lobectomy for neonatal hyperfunctioning adenoma related to a somatic TSHr gene mutation. Ann Endocrinol (Paris) 2012 0.75
53 18F-FDG PET/CT of Brown Adipose Tissue Hyperactivation Associated With Pregnancy and Paraganglioma. Clin Nucl Med 2017 0.75
54 Lobular breast carcinoma: a case of rare possible 18F-FDG PET/CT and bone scan false negative. Clin Nucl Med 2015 0.75
55 Radioguided surgery and systemic radionuclide therapy of neuroendocrine tumours. In Vivo 2010 0.75
56 The labeled-leukocyte scan in the study of abdominal abscesses. Mol Imaging Biol 2010 0.75
57 Colorectal cancer: translation of biological pathways into molecular imaging. Nucl Med Commun 2012 0.75
58 18F-FDG PET/CT lung 'focalities' without coregistered CT findings: an interpretative clinical dilemma. Nucl Med Commun 2015 0.75
59 Axillary lymph node metastases detection with 99mTc-sestamibi scintimammography in patients with breast cancer undergoing curative surgery. Anticancer Res 2007 0.75
60 Sentinel Lymph Node Biopsy in Breast Cancer: Indications, Contraindications, and Controversies. Clin Nucl Med 2016 0.75
61 18F-FDG PET/CT of Generalized Arteritis. Clin Nucl Med 2018 0.75
62 Potential role of FDG PET/CT in evaluating patients with hepatic incidentalomas. Clin Nucl Med 2014 0.75
63 Monthly ibandronate versus weekly risedronate treatment for low bone mineral density in stable renal transplant patients. Nucl Med Commun 2015 0.75
64 Are PREDIST criteria better than PERCIST criteria as a PET predictor of preoperative treatment response in rectal cancer? Nucl Med Commun 2014 0.75
65 Positron-emission tomography in gynaecologic malignancies. Arch Gynecol Obstet 2009 0.75
66 Monte Carlo simulation of electron dose from (131)I-targeted tumor cells within a heterogeneous tumor. Cancer Biother Radiopharm 2011 0.75
67 DXA variations and fractures after simultaneous pancreas-renal transplantation: results of a long-term follow-up. Clin Nucl Med 2015 0.75
68 68Ga DOTANOC PET/CT detects primary malignant insulinoma. Clin Nucl Med 2015 0.75
69 Nuclear medicine imaging of endocrine neoplasms. Nucl Med Commun 2014 0.75
70 Biological target volume overlapping segmentation system method for avoiding false-positive PET findings in assessing response to neoadjuvant chemoradiation therapy in rectal cancer. Clin Nucl Med 2014 0.75
71 Additional diagnostic value of hybrid SPECT-CT systems imaging in patients with differentiated thyroid cancer. Am J Clin Oncol 2014 0.75
72 A very rare case of nonfunctioning pituitary adenoma incidentally disclosed at 18F-FDG PET/CT. Clin Nucl Med 2012 0.75
73 FDG PET/CT in Aortic Valve Bioprosthesis Infection. Clin Nucl Med 2017 0.75